Metformin Vitabalans

Metformin, the active ingredient in Metformin Vitabalans, is a biguanide presented as an oral tablet for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus.

GNH USA supplies Metformin Vitabalans as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Vitabalans belongs to the biguanide class and is employed in the management of disorders of glucose metabolism.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels and helps achieve target HbA1c values.

Metformin Vitabalans may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often early in therapy. - Abdominal discomfort: cramping or pain. - Metallic taste: transient alteration of taste perception. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: reduced absorption over long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatotoxicity: abnormal liver function tests. - Hypoglycemia: uncommon when used alone. - Anemia: due to B12 deficiency. - Acute pancreatitis: very rare occurrence.

Metformin Vitabalans requires careful consideration of patient‑specific factors before initiation.

- Renal function: avoid or adjust dose in patients with impaired creatinine clearance. - Hepatic impairment: use with caution in liver disease. - Contrast imaging: discontinue before iodinated contrast procedures. - Alcohol consumption: limit intake to reduce lactic acidosis risk. - Elderly patients: monitor for renal function and dehydration. - Pregnancy category: safety not established; assess risk‑benefit. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin Vitabalans can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of lactic acidosis. - Cimetidine: may raise metformin plasma concentrations. - Alcohol: potentiates lactic acidosis. - Diuretics (loop or thiazide): may impair renal clearance. - Antiretrovirals (e.g., didanosine): heightened toxicity risk.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function and potassium. - Beta‑blockers: may mask hypoglycemia symptoms. - Other antidiabetic agents: adjust dose to avoid hypoglycemia. - Thyroid hormones: may affect glucose metabolism. - Digoxin: monitor for altered renal clearance.